Focada exclusivamente no desenvolvimento, 
                                        produção e promoção de produtos farmacêuticos especializados

News

26/08/2020 MATERIAL FACT – SQUEEZE-OUT
14/08/2020 Material Fact – Public Offer Auction*
15/07/2020 Notice to the Market –  Alienation Statement of Relevant Stake – Hix Investimentos Ltda*
15/07/2020 Material Fact – Launching Of Tender Offer
08/07/2020 Material Fact – Approval of Tender Offer
23/06/2020 Management Report 1Q20 Results
29/05/2020 Notice to the Market – 1Q20 Results Release Date
19/05/2020 Material Fact – Unified Tender Offer – Update
01/04/2020 Notice to the Market – Unified Tender Offer
30/03/2020 2019 Results
29/11/2019 Material Fact – Sale of Control – Closing
12/11/2019 3Q19 Earnings Release
01/11/2019 3Q19 Earnings Release Schedule
28/10/2019 Material Fact – Sale of Control – Update
21/10/2019 Material Fact – Grupo Biotoscana Announces Change in Management
21/10/2019 Material Fact – Sale of Control
12/08/2019 2Q19 Earnings Release
12/08/2019 Notice to the Market – Management Change
13/05/2019 1Q19 Earnings Release
26/04/2019 1Q19 Earnings Release Calendar
10/04/2019 4Q18 and 2018 Earnings Release
20/02/2019 4Q18 and 2018 Earnings Release Calendar
12/11/2018 3Q18 Earnings Release
23/10/2018 3Q18 Earnings Release Schedule
19/10/2018 Notice to the Market – Change in Board of Directors
04/10/2018 Notice to the Market – New regulatory approvals
31/08/2018 Material Fact – Change in management
14/08/2018 2Q18 Earnings Release
23/07/2018 2Q18 Earnings Release Schedule
29/06/2018 Notice to the Market – Management change
28/06/2018 Notice to the Market – Approval of CRESEMBA and ZEVTERA in Peru
10/05/2018 1Q18 Earnings Release
10/05/2018 Notice to the Market – Extension of agreement with Gilead
25/04/2018 Material Fact – BDR Buyback Program
24/04/2018 1Q18 Earnings Release Schedule
20/03/2018 4Q17 Earnings Release
13/03/2018 Material Fact – Contract expiration with Actelion
12/03/2018 Notice to the Market – New initiatives for LENVIMA
06/03/2018 Notice to the Market – Launch of ZEVTERA in Argentina
02/03/2018 Notice to the Market – Extension of agreement with Biocad
19/02/2018 4Q17 and 2017 Earnings Release Schedule
15/02/2018 Notice to the Market – Hiring of Vice-President of Operations
29/12/2017 Notice to the Market – Loan prepayment
15/12/2017 Notice to the Market – Hiring of Vice-President of R&D
05/12/2017 Notice to the Market – HARVONI® approved in Brazil
13/11/2017 3Q17 Earnings Release
13/11/2017 Material Fact – Acquisiton of Laboratio DOSA
10/11/2017 Notice to the Market – Election of new member of the Accounting Audit Committee
01/11/2017 Notice to the Market – Grupo Biotoscana announces the launch of ABRAXANE / ABRAXUS
24/10/2017 Material Fact – Management Restructure
23/10/2017 3Q17 Earnings Release Schedule
09/10/2017 Material Fact – Hiring of market maker
03/10/2017 Notice to the Market – Agreement with Eisai
22/09/2017 Notice to the Market – Hiring of market maker
30/08/2017 Notice to the Market – Grupo Biotoscana expands its partnership with Gilead Sciences in HCV in Brazil
30/08/2017 Notice to the Market – Acquisition of Relevant Interest – GIC Private Limited
21/08/2017 Notice to the Market – Acquisition of Relevant Interest – JP Morgan Chase & Co.
21/08/2017 Notice to the Market – Alienation of Relevant Interest – JP Morgan Chase
15/08/2017 2Q17 Earnings Release
09/08/2017 Closing Announcement*
28/07/2017 2Q17 Earnings Release Schedule
24/07/2017 IPO announcement *
12/06/2017 Extended partnership for 15 years and expand footprint to include Brazil
01/03/2017 GBT appoints new President and Chief Operating Officer
02/02/2017 Biotoscana, the local pharmaceutical company that became a Latin-American one